Mounjaro vs Trulicity

Summary: Mounjaro and Trulicity are both once-weekly Eli Lilly injections for type 2 diabetes, but Mounjaro (a dual GIP/GLP-1 agonist) lowers A1C and weight more, while Trulicity (a GLP-1 only) has the simpler pen and the only FDA cardiovascular indication.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Mounjaro is the stronger drug. Trulicity is the easier drug. Both are once-weekly subcutaneous injections from Eli Lilly for type 2 diabetes, but Mounjaro (tirzepatide) hits two gut-hormone receptors while Trulicity (dulaglutide) hits one. At maximum dose, Mounjaro lowers A1C by roughly 2.0 to 2.4 percentage points; Trulicity tops out around 1.5 to 1.8. Average weight loss tells the same story: about 25 pounds on 15 mg Mounjaro versus about 10 pounds on 4.5 mg Trulicity. Trulicity wins back ground in one place that actually matters: it is the only one of the two with an FDA-approved indication for reducing cardiovascular events ^[2][4].

Here is the full side-by-side, with the trial data, the side effect rates, and the practical stuff that decides which one ends up in your fridge.

Quick comparison

What each drug actually is

Trulicity is dulaglutide, a glucagon-like peptide-1 receptor agonist. One receptor, one mechanism. It mimics the gut hormone GLP-1, which tells the pancreas to release insulin when blood sugar rises, slows gastric emptying, and dampens appetite. FDA approval came in 2014, making it one of the older weekly GLP-1s on the market.

Mounjaro is tirzepatide, a dual agonist. It activates the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor at the same time. GIP is the second major incretin hormone. Adding GIP activity on top of GLP-1 produces stronger effects on insulin secretion, appetite, and fat storage. FDA approval for type 2 diabetes came in 2022, eight years after Trulicity ^[1][2].

Both are made by Eli Lilly. Both are weekly injections. Both have the same FDA boxed warning for thyroid C-cell tumors based on rodent studies, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

A1C reduction: where Mounjaro pulls ahead

This is the cleanest difference between the two drugs.

In SURPASS-1, the 40-week monotherapy trial that supported Mounjaro's FDA approval, tirzepatide lowered A1C by 1.87% at 10 mg and 2.07% at 15 mg in adults whose diabetes was inadequately controlled on diet and exercise alone ^[3]. The corresponding dulaglutide data from the AWARD trial program comes in lower. Trulicity 1.5 mg, the dose that the REWIND cardiovascular trial used, lowered A1C by about 0.8 to 1.0%. Higher doses studied later (3 mg and 4.5 mg) pushed that to roughly 1.6 to 1.8% in metformin-treated patients ^[5].

A head-to-head Japanese phase 3 trial that compared tirzepatide directly with dulaglutide 0.75 mg (Japan's standard dose) found A1C reductions of 2.4 to 2.8% on Mounjaro versus 1.3% on Trulicity over 52 weeks. SURPASS-CVOT, the large cardiovascular outcomes trial Lilly published in 2025, compared Mounjaro head-to-head against Trulicity 1.5 mg over five years and found Mounjaro produced larger A1C and weight changes throughout follow-up ^[5].

No SURPASS trial compared maximum-dose Mounjaro (15 mg) head-to-head against maximum-dose Trulicity (4.5 mg). The strongest direct comparisons used Trulicity 1.5 mg, which is lower than the current US max. Cross-trial inference still favors Mounjaro at every comparable dose tier, and the gap widens at higher doses where Trulicity has nowhere left to titrate.

Weight loss: a bigger gap than the A1C numbers suggest

Neither drug is FDA-approved for weight loss. Both produce it as a side effect.

Trulicity averages around 5 to 10 pounds of weight loss in type 2 diabetes trials at the 1.5 mg dose, with the higher doses (3 mg and 4.5 mg) pushing closer to 10 to 12 pounds in AWARD-11. Mounjaro at 15 mg produces an average weight loss of roughly 20 to 25 pounds (about 13 to 15% of body weight) in type 2 diabetes patients across the SURPASS program. In SURPASS-2, which compared Mounjaro to semaglutide (Ozempic), the 15 mg arm averaged 11.2 kg (about 25 pounds) of weight loss ^[5].

The dose-response curve also runs differently. Trulicity weight loss plateaus relatively early. Mounjaro continues to deliver additional weight loss at each higher dose, which is why Lilly was able to spin off the same molecule as Zepbound, the FDA-approved obesity drug.

For a patient with type 2 diabetes who also wants to lose 30 or 40 pounds, Mounjaro is the obvious tool. For a patient at a healthy weight who needs A1C control and nothing else, Trulicity is plenty for many people and easier on the GI tract.

Side effects: similar profile, different intensity

Both drugs cause the same family of gastrointestinal side effects. Mounjaro's are more frequent and more intense at the higher doses, which mirrors the efficacy pattern. There is no free lunch with these drugs: stronger appetite suppression and stronger glucose lowering ride together with stronger nausea and more diarrhea.

Both labels include warnings for pancreatitis, gallbladder disease, kidney injury (usually from dehydration during severe GI side effects), hypoglycemia when combined with insulin or sulfonylureas, severe allergic reactions, and rare reports of ileus ^[1][2]. Both have the same FDA boxed warning for thyroid C-cell tumors.

The honest summary: if you have struggled with nausea on Trulicity, you will likely struggle on Mounjaro too, possibly more so at the higher doses. If you tolerated Trulicity fine, you will likely tolerate Mounjaro's starting dose (2.5 mg) without much trouble. The titration matters. Both drugs are designed to be escalated slowly so the gut adapts.

Ease of use: Trulicity's strongest argument

The Trulicity pen is one of the friendliest auto-injectors in pharma. You uncap, place the green base against your skin, press the button, and wait for a second click. You do not see the needle. You do not measure anything. The pen does everything except choose the injection site.

The Mounjaro KwikPen is similar but not identical. You uncap, hold against the skin, press the button, hold for ten seconds, and listen for the second click. Most patients find it nearly as easy as Trulicity, but the needle is visible briefly when you uncap, and the device is slightly bulkier. Mounjaro is also available as a single-dose vial, which gives prescribers the option of insulin-syringe administration but adds a small math step for the patient.

For someone with poor manual dexterity, vision issues, or needle phobia, the Trulicity pen has a real edge. For most people, the difference between the two devices is small enough that the efficacy gap dominates the decision.

Cardiovascular outcomes: where Trulicity earned its label

The REWIND trial, published in The Lancet in 2019, followed almost 10,000 adults with type 2 diabetes for an average of 5.4 years. Trulicity 1.5 mg cut the rate of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 12% versus placebo ^[4]. That result earned Trulicity the FDA indication for reducing cardiovascular event risk in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors. It is the only weekly GLP-1 with this label.

Mounjaro does not yet carry the same indication, but the SURPASS-CVOT trial published in 2025 changes the picture. Lilly reported that Mounjaro met its primary endpoint of cardiovascular protection in a head-to-head against Trulicity, reinforcing its benefit in type 2 diabetes patients with heart disease. The FDA has not yet updated the Mounjaro label to add a cardiovascular indication, but the data is in the public record and many endocrinologists already prescribe Mounjaro to high-CV-risk patients on the strength of those results ^[5].

If a cardiovascular event reduction indication is the deciding factor for an insurance authorization or a prescribing decision today, Trulicity still has the label. By 2027 that may no longer be true.

Cost

List prices are close: about $990 per month for Trulicity, about $1,080 per month for Mounjaro ^[5]. Neither drug has a generic or biosimilar yet. Both use the same Eli Lilly savings card program for commercially insured patients (typical out-of-pocket of $25 to $100 per month when coverage applies) and the same Lilly Cares Foundation for income-qualified uninsured patients.

Real out-of-pocket cost depends on whether your insurance plan covers the medication, which tier it sits on, and whether your prescriber needs to demonstrate "step therapy" failure on a cheaper drug first. Most US commercial plans that cover one weekly GLP-1 cover the other, so cost is rarely the deciding factor between Trulicity and Mounjaro specifically. It is much more often the deciding factor between a weekly GLP-1 and an older oral drug like metformin or a sulfonylurea.

Pediatric use

Trulicity is FDA-approved for children 10 years and older with type 2 diabetes. Mounjaro is approved only for adults ^[1][2]. If you are choosing a weekly injection for a pediatric type 2 diabetes patient, Trulicity is the only one of the two on-label. (A pediatric tirzepatide trial called SURPASS-PEDS has reported strong A1C reductions, but the label has not yet been expanded.)

Switching from Trulicity to Mounjaro

This is the most common direction of switch. The mechanics are simple and well-documented ^[5]:

1. Take your last scheduled Trulicity dose on your normal weekly injection day.
2. Wait one week (the normal Trulicity interval).
3. Start Mounjaro at 2.5 mg, regardless of which Trulicity dose you were on.
4. Titrate Mounjaro on the standard schedule: 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then up by 2.5 mg every 4 weeks as tolerated.

You do not start Mounjaro at a "matched" dose. There is no conversion chart in FDA guidance because the two drugs have different mechanisms and different per-milligram potencies. Starting low and titrating up protects you from a side effect surge.

Most patients tolerate the switch well. Some have a brief uptick in nausea or appetite suppression in the first two to four weeks as the GIP component kicks in. By week 6 or 8, most people are at 5 mg or 7.5 mg of Mounjaro and seeing better glucose control than they had on max-dose Trulicity.

Switching the other direction (Mounjaro to Trulicity) is less common but works the same way. Stop Mounjaro, wait a week, start Trulicity at 0.75 mg, titrate up as needed. Expect to lose some of the A1C and weight benefit you gained, since Trulicity's ceiling is lower.

How Mounjaro and Trulicity compare to Ozempic, Wegovy, and Zepbound

For context, here is where the two drugs sit in the broader weekly GLP-1 landscape:

• Ozempic (semaglutide): GLP-1 only, made by Novo Nordisk, approved for type 2 diabetes and cardiovascular event reduction. Roughly equivalent to Trulicity at low doses, more potent at the 2 mg dose. Both Trulicity and Ozempic are GLP-1-only competitors. SURPASS-2 showed Mounjaro 15 mg beat Ozempic 1 mg on A1C reduction by about 0.5 percentage points and on weight loss by about 13 pounds.
• Wegovy (semaglutide 2.4 mg): same molecule as Ozempic, higher dose, FDA-approved for chronic weight management. Trulicity does not have a higher-dose obesity counterpart. Mounjaro does (Zepbound).
• Zepbound (tirzepatide): same molecule as Mounjaro, FDA-approved for chronic weight management in adults with obesity or overweight plus a comorbidity. Same pen, same dosing schedule, different label. If your goal is weight loss and you have obesity but not type 2 diabetes, Zepbound is the on-label tirzepatide product.
• Rybelsus (oral semaglutide): oral GLP-1 tablet, lower efficacy than weekly injectables, taken daily on an empty stomach. Easier for needle-averse patients, less effective overall than either Trulicity or Mounjaro on A1C and weight.

For pure type 2 diabetes A1C control and weight loss, the current efficacy ranking at maximum dose is roughly: Mounjaro > Ozempic 2 mg > Trulicity 4.5 mg > Rybelsus 14 mg. For cardiovascular event reduction, Trulicity, Ozempic, and (per SURPASS-CVOT) Mounjaro all show benefit, though only the first two carry the FDA indication today.

Who should pick Trulicity

• You have type 2 diabetes plus established cardiovascular disease or risk factors and want a drug with an FDA cardiovascular indication.
• You are between 10 and 17 years old with type 2 diabetes (Mounjaro is not approved in this age group).
• You had significant GI side effects on a prior GLP-1 and want the gentler titration.
• You strongly prefer the single-button, no-needle-visible auto-injector.
• Your A1C is close to target on metformin alone and you need a moderate added agent rather than a maximally potent one.

Who should pick Mounjaro

• You have type 2 diabetes and your A1C remains above target despite metformin plus a GLP-1.
• You need substantial weight loss alongside diabetes control (20+ pounds).
• You have already tried max-dose Trulicity and want a stronger drug.
• You want the option to escalate doses further if early results plateau (Mounjaro has six dose tiers versus Trulicity's four).
• You are willing to trade somewhat higher GI side effect risk for substantially better metabolic results.

Common questions

Is Mounjaro stronger than Trulicity?

Yes. At maximum dose Mounjaro lowers A1C by about 2.0 to 2.4% versus 1.5 to 1.8% for Trulicity, and produces roughly 25 lb of weight loss versus 10 lb. The dual GIP and GLP-1 mechanism is the reason.

Are Mounjaro and Trulicity the same drug?

No. Both are made by Eli Lilly, but Trulicity is dulaglutide (a GLP-1 agonist only) and Mounjaro is tirzepatide (a dual GIP and GLP-1 agonist). Different molecules, different mechanisms, different doses.

Can you switch from Trulicity to Mounjaro?

Yes. Take your last Trulicity dose, wait one week, then start Mounjaro at 2.5 mg regardless of what Trulicity dose you were on. Titrate up every 4 weeks as tolerated under prescriber supervision.

Is Trulicity better than Mounjaro for the heart?

Trulicity has the only FDA indication for cardiovascular event reduction based on the REWIND trial. Mounjaro showed cardiovascular benefit in SURPASS-CVOT (2025) but does not yet carry the label.

Which has worse side effects, Mounjaro or Trulicity?

Both cause nausea, diarrhea, and vomiting in the first weeks. Rates are similar at low doses. At max dose Mounjaro (15 mg) has higher nausea (about 29% versus 21% for Trulicity 4.5 mg) but the side effects are dose-dependent for both drugs.

How does Trulicity compare to Ozempic?

Both are once-weekly GLP-1 agonists with cardiovascular indications. Ozempic 2 mg is somewhat more potent on A1C and weight than Trulicity 4.5 mg. Trulicity is approved down to age 10; Ozempic is adult-only.

How does Trulicity compare to Wegovy?

Wegovy is high-dose semaglutide approved for weight loss; Trulicity is dulaglutide approved for type 2 diabetes. Wegovy produces about 15% body weight loss versus about 5 to 7% for Trulicity. Different indications, different goals.

What about Trulicity versus Zepbound?

Zepbound is tirzepatide (same molecule as Mounjaro) approved for weight management. It produces about 21% body weight loss at the 15 mg dose versus about 5 to 7% on Trulicity. For weight loss specifically, Zepbound is dramatically more effective.

How does Rybelsus compare to Trulicity?

Rybelsus is oral semaglutide taken daily as a tablet. Trulicity is injected weekly. Rybelsus avoids needles but is less effective on A1C and weight than weekly injectables and requires strict empty-stomach dosing.

Can children take Mounjaro?

No. Mounjaro is FDA-approved for adults only. Trulicity is the weekly GLP-1 option for type 2 diabetes patients aged 10 and older.

Do Mounjaro and Trulicity cost the same?

List prices are close, about $1,080 per month for Mounjaro and about $990 for Trulicity. Both have Eli Lilly savings cards that drop commercially insured cost to around $25 per month for type 2 diabetes patients.

Is Trulicity easier to inject than Mounjaro?

Slightly. The Trulicity pen is one of the simplest auto-injectors on the market: cap off, press button, done. Mounjaro's KwikPen is similar but the needle is briefly visible after uncapping. The functional difference is small for most patients.